argenex (ARGX) Stock Price, News & Analysis

Company Overview

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn). They are used in certain patients with generalized myasthenia gravis, and efgartigimod has also received regulatory approvals for chronic inflammatory demyelinating polyneuropathy and other indications in selected markets.

Founded in 2008, argenx is headquartered in Ghent, Belgium, with operations and commercial activities in the United States and other international markets. The company continues to develop efgartigimod for additional autoimmune conditions and maintains a broader pipeline of investigational therapies. Tim Van Hauwermeiren serves as chief executive officer.

Key Stats

• Today's Range: $787.73 to $832.24
• 50-Day Range: $818.63 to $1,058.90
• 52-Week Range: $661.85 to $1,072.75
• Volume: 2.45 million shs
• Average Volume: 277,477 shs
• Market Capitalization: $51.21 billion
• P/E Ratio: 31.44
• Dividend Yield: N/A
• Price Target: $1,158.61
• Consensus Rating: Moderate Buy

argenex Stock Analysis - MarketRank™

argenex scored higher than 94% of companies evaluated by MarketBeat, and ranked 31st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

argenex has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 17 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

argenex has a consensus price target of $1,158.61, representing about 41.5% upside from its current price of $818.63.

Amount of Analyst Coverage

argenex has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 30.21%

Earnings Growth

Earnings for argenex are expected to grow by 30.21% in the coming year, from $28.83 to $37.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of argenex is 31.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of argenex is 31.44, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.66.

Price to Earnings Growth Ratio

argenex has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.

Price to Book Value per Share Ratio

argenex has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.15% of the float of argenex has been sold short.

Short Interest Ratio / Days to Cover

argenex has a short interest ratio ("days to cover") of 6.31.

Change versus previous month

Short interest in argenex has recently increased by 4.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

argenex does not currently pay a dividend.

Dividend Growth

argenex does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.21

News Sentiment

argenex has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for argenex this week, compared to 8 articles on an average week.

Search Interest

19 people have searched for ARGX on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.

MarketBeat Follows

8 people have added argenex to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, argenex insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.43% of the stock of argenex is held by insiders.

Percentage Held by Institutions

60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/21/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARGX
• Previous Symbol: NASDAQ:ARGX
• CIK: 1697862
• Web: www.argenx.com
• Phone: (176) 303-0488
• Fax: N/A
• Employees: 1,863
• Year Founded: 2008

Price Target and Rating

• Average Price Target for argenex: $1,158.61
• High Price Target: $1,415.00
• Low Price Target: $910.00
• Potential Upside/Downside: +41.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $26.04
• Trailing P/E Ratio: 31.44
• Forward P/E Ratio: 28.40
• P/E Growth: 0.97
• Net Income: $1.29 billion
• Net Margins: 32.19%
• Pretax Margin: 32.80%
• Return on Equity: 43.59%
• Return on Assets: 36.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.12
• Quick Ratio: 4.89

Sales & Book Value

• Annual Sales: $5.23 billion
• Price / Sales: 9.80
• Cash Flow: $18.81 per share
• Price / Cash Flow: 43.52
• Book Value: $118.34 per share
• Price / Book: 6.92

Miscellaneous

• Outstanding Shares: 62,561,000
• Free Float: 61,041,000
• Market Cap: $51.21 billion
• Optionable: Optionable
• Beta: 0.44